Bonhin Rodrigo Gonzalez, de Carvalho Guilherme Machado, Guimarães Alexandre Caixeta, Rocha Vanessa Brito, Chone Carlos Takahiro, Crespo Agrício Nubiato, Amstalden Eliane Maria
Department of Otolaryngology-Head and Neck Surgery, Faculty of Medical Sciences, University of Campinas, Rua Tessália Vieira de Carvalho, 126 - CEP: 13083-887, Campinas, São Paulo, Brazil.
Ear Nose Throat J. 2017 Apr-May;96(4-5):176-182.
The prognosis and survival of patients with laryngeal and hypopharyngeal squamous cell carcinoma (SCC) are related to the clinical staging. Tumor growth and metastasis are closely related to angiogenesis. Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX-2) are intimately related to the angiogenic process in which the blood supply required for neoplastic evolution is ensured. Considering the contributions of VEGF and COX-2 to the formation, growth, and progression of primary tumors, as well as their metastasis, it has been thought that the expression of these two factors might be related to the size and/or aggressiveness of laryngeal and hypopharyngeal cancer. To test that theory, we conducted a retrospective study to evaluate the expression of VEGF and COX-2 markers in archived specimens of SCC of the larynx and hypopharynx to correlate their expression with tumor size. These specimens had been obtained from 35 patients-31 men and 4 women, aged 37 to 75 years (mean: 57)-who had been treated for laryngeal or hypopharyngeal SCC at our tertiary care university hospital over a period of 15 years. Immunohistochemical analyses were performed with avidin-biotin-peroxidase staining for VEGF and COX-2 antibodies. The degree of VEGF and COX-2 expression was based on the German scale of immunoreactivity. Specimens were separated into groups based on the intensity of expression (none/low and moderate/strong) and tumor size (TNM categories T1/T2 and T3/T4). A total of 7 patients exhibited moderate or strong VEGF expression (3 from the T1/T2 group and 4 from the T3/T4 group), and 17 patients demonstrated moderate or strong COX-2 expression (8 from the T1/T2 group and 9 from the T3/T4 group). We found no statistically significant relationship between tumor size and either VEGF or COX-2 expression. Our study demonstrated that despite the intrinsic connection between and VEGF and COX-2, neither appears to be related to the size of the SCCs of the larynx or hypopharynx. Other factors must be involved in the pathogenesis and progression of this disease, and further studies are needed to identify them.
喉及下咽鳞状细胞癌(SCC)患者的预后和生存期与临床分期相关。肿瘤生长和转移与血管生成密切相关。血管内皮生长因子(VEGF)和环氧合酶2(COX - 2)与血管生成过程密切相关,血管生成过程确保了肿瘤发展所需的血液供应。考虑到VEGF和COX - 2对原发性肿瘤的形成、生长和进展及其转移的作用,人们认为这两种因子的表达可能与喉癌和下咽癌的大小和/或侵袭性有关。为了验证这一理论,我们进行了一项回顾性研究,以评估VEGF和COX - 2标志物在喉和下咽SCC存档标本中的表达,并将它们的表达与肿瘤大小相关联。这些标本取自35例患者,其中31例男性和4例女性,年龄在37至75岁之间(平均57岁),他们在我们的三级大学附属医院接受了15年的喉或下咽SCC治疗。采用抗生物素蛋白 - 生物素 - 过氧化物酶染色对VEGF和COX - 2抗体进行免疫组织化学分析。VEGF和COX - 2的表达程度基于德国免疫反应量表。标本根据表达强度(无/低和中度/强)和肿瘤大小(TNM分类T1/T2和T3/T4)分组。共有7例患者表现出中度或强VEGF表达(T1/T2组3例,T3/T4组4例),17例患者表现出中度或强COX - 2表达(T1/T2组8例,T3/T4组9例)。我们发现肿瘤大小与VEGF或COX - 2表达之间无统计学显著关系。我们的研究表明,尽管VEGF和COX - 2之间存在内在联系,但两者似乎均与喉或下咽SCC的大小无关。该疾病的发病机制和进展肯定涉及其他因素,需要进一步研究来确定它们。